Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 45, Issue 4, pp 496–503 | Cite as

Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis

  • Fabio Mangiacapra
  • Iginio Colaiori
  • Elisabetta Ricottini
  • Antonio Creta
  • Giuseppe Di Gioia
  • Ilaria Cavallari
  • Edoardo Bressi
  • Marialessia Capuano
  • Emanuele Barbato
  • Germano Di Sciascio
Article

Abstract

We investigated the impact of suboptimal platelet reactivity on clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients with stable coronary artery disease undergoing elective PCI. Platelet reactivity was measured before PCI using the VerifyNow P2Y12 assay. Primary endpoint was the incidence of ischemic or bleeding events at 1 month and 5 years. Patients with high platelet reactivity (HPR) showed significantly higher rates of ischemic events both during the 1st month after PCI (HR 2.06, 95% CI 1.02–4.06), and beyond 1 month compared with patients without HPR (HR 1.73, 95% CI 1.02–2.95). Conversely, compared with patients without low platelet reactivity (LPR), patients with LPR presented significantly higher rates of bleeding only during the 1st month (HR 3.67, 95% CI 1.68–8.02). In conclusion, pre-procedural HPR is associated with ischemic events even beyond the 1st month after PCI. The association of LPR with bleeding events seems to be confined to the periprocedural period.

Keywords

Platelet function test Percutaneous coronary intervention Coronary artery disease 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Authors/Task Force Members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefGoogle Scholar
  2. 2.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516CrossRefPubMedGoogle Scholar
  3. 3.
    Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D’Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G (2012) A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 5:281–289CrossRefPubMedGoogle Scholar
  4. 4.
    Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762–1771CrossRefPubMedGoogle Scholar
  5. 5.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCTFFUDOMI, Authors/Task FMC, Thygesen K, Alpert JS, White HD, Biomarker S, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman ECGS., Clemmensen BR, Johanson PM, Hod P, Imaging H, Underwood S, Bax R, Bonow JJ, Pinto JJ, Gibbons F, Classification RJ, Fox S, Atar KA, Newby D, Galvani LK, Hamm M, Intervention CW, Uretsky S, Steg BF, Wijns PG, Bassand W, Menasche JP, Ravkilde P, Trials J, Ohman RS, Antman EM, Wallentin EM, Armstrong LC, Simoons PW, Trials ML, Januzzi RS, Nieminen JL, Gheorghiade MS, Filippatos M, Trials G, Luepker RS, Fortmann RV, Rosamond SP, Levy WD, Wood D, Trials D, Smith RS, Hu SC, Lopez-Sendon D, Robertson JL, Weaver RM, Tendera D, Bove M, Parkhomenko AA, Vasilieva AN, Mendis EJ S, ESC Committee for Practice Guidelines CPG, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefPubMedGoogle Scholar
  6. 6.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic RC (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMedGoogle Scholar
  7. 7.
    Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11CrossRefPubMedGoogle Scholar
  8. 8.
    Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. J Thromb Thrombolysis 32:64–71CrossRefPubMedGoogle Scholar
  9. 9.
    Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Muller O, Barbato E, Di Sciascio G (2010) Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 106:619–623CrossRefPubMedGoogle Scholar
  10. 10.
    Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E (2010) High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:35–40CrossRefPubMedGoogle Scholar
  11. 11.
    Mangiacapra F, Barbato E (2013) Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res 6:310–315CrossRefPubMedGoogle Scholar
  12. 12.
    Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E (2010) Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 105:333–338CrossRefPubMedGoogle Scholar
  13. 13.
    Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Wijns W, Di Sciascio G (2010) Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:318–323CrossRefPubMedGoogle Scholar
  14. 14.
    Mangiacapra F, Bartunek J, Bijnens N, Peace AJ, Dierickx K, Bailleul E, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, Rutten M, De Bruyne B, Wijns W, van de Vosse F, Barbato E (2012) Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 10:2452–2461CrossRefPubMedGoogle Scholar
  15. 15.
    Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G (2015) High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a significant association beyond definitions. Int J Cardiol 190:124–125CrossRefPubMedGoogle Scholar
  16. 16.
    Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC (2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 77:1020–1030CrossRefPubMedGoogle Scholar
  17. 17.
    Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal CS (2006) Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48:1765–1770CrossRefPubMedGoogle Scholar
  18. 18.
    Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G, ARCTIC I (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109CrossRefPubMedGoogle Scholar
  19. 19.
    Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS I (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105CrossRefPubMedGoogle Scholar
  20. 20.
    Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164CrossRefPubMedGoogle Scholar
  21. 21.
    Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E (2016) Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective PCI. J Am Coll Cardiol 68:235–237CrossRefPubMedGoogle Scholar
  22. 22.
    Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G (2016) Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Circulation 134:835–837CrossRefPubMedGoogle Scholar
  23. 23.
    Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI SCAI (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMedGoogle Scholar
  24. 24.
    Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT SI (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRefPubMedGoogle Scholar
  25. 25.
    Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H (2017) Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 38:1048–1055CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mangiacapra F, Ricottini E, Barbato E, Demartini C, Peace A, Patti G, Vizzi V, De Bruyne B, Wijns W, Di Sciascio G (2015) Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score. Circ Cardiovasc Interv 8:e002106CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Fabio Mangiacapra
    • 1
  • Iginio Colaiori
    • 1
  • Elisabetta Ricottini
    • 1
  • Antonio Creta
    • 1
  • Giuseppe Di Gioia
    • 1
  • Ilaria Cavallari
    • 1
  • Edoardo Bressi
    • 1
  • Marialessia Capuano
    • 1
  • Emanuele Barbato
    • 2
    • 3
  • Germano Di Sciascio
    • 1
  1. 1.Unit of Cardiovascular Science, Department of MedicineCampus Bio-Medico UniversityRomeItaly
  2. 2.Cardiovascular Research Center AalstOLV HospitalAalstBelgium
  3. 3.Department of Advanced Biomedical SciencesUniversity of Naples Federico IINaplesItaly

Personalised recommendations